Last week the annual World Hepatitis Day was held, and campaigners have called on all strains of viral hepatitis – dominated by hep C and hep B - to be eliminated by 2030.

GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, will get a rapid six-month review from the FDA when it is filed for approval, said the drugmaker this morning.

Objective The significance of the liver-microbiome axis has been increasingly recognised as a major modulator of autoimmunity. The aim of this study was to take advantage of a large well-defined ...